The stock of Cara Therapeutics Inc (CARA) has seen a -3.36% decrease in the past week, with a -11.89% drop in the past month, and a 37.72% flourish in the past quarter. The volatility ratio for the week is 8.19%, and the volatility levels for the past 30 days are at 8.55% for CARA. The simple moving average for the last 20 days is -0.80% for CARA’s stock, with a simple moving average of -43.95% for the last 200 days.
Is It Worth Investing in Cara Therapeutics Inc (NASDAQ: CARA) Right Now?
The stock has a 36-month beta value of 0.82. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CARA is 46.47M, and at present, short sellers hold a 5.61% of that float. On May 09, 2024, the average trading volume of CARA was 607.00K shares.
CARA) stock’s latest price update
Cara Therapeutics Inc (NASDAQ: CARA) has experienced a decline in its stock price by -7.46 compared to its previous closing price of 0.79. However, the company has seen a fall of -3.36% in its stock price over the last five trading days. GlobeNewsWire reported 2024-05-06 that STAMFORD, Conn., May 06, 2024 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will report first quarter 2024 financial results on Monday, May 13, 2024, after the U.S. markets close. The press release will be available under “Press Releases” in the Investors section of the Company’s website at www.CaraTherapeutics.com.
Analysts’ Opinion of CARA
Many brokerage firms have already submitted their reports for CARA stocks, with BofA Securities repeating the rating for CARA by listing it as a “Underperform.” The predicted price for CARA in the upcoming period, according to BofA Securities is $6 based on the research report published on March 08, 2023 of the previous year 2023.
JP Morgan, on the other hand, stated in their research note that they expect to see CARA reach a price target of $20, previously predicting the price at $17. The rating they have provided for CARA stocks is “Overweight” according to the report published on March 08th, 2022.
Canaccord Genuity gave a rating of “Buy” to CARA, setting the target price at $33 in the report published on November 01st of the previous year.
CARA Trading at -11.91% from the 50-Day Moving Average
After a stumble in the market that brought CARA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.30% of loss for the given period.
Volatility was left at 8.55%, however, over the last 30 days, the volatility rate increased by 8.19%, as shares sank -9.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.46% lower at present.
During the last 5 trading sessions, CARA fell by -3.36%, which changed the moving average for the period of 200-days by -74.63% in comparison to the 20-day moving average, which settled at $0.7351. In addition, Cara Therapeutics Inc saw -1.33% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CARA starting from Posner Christopher, who sale 3,936 shares at the price of $0.75 back on May 02 ’24. After this action, Posner Christopher now owns 176,585 shares of Cara Therapeutics Inc, valued at $2,952 using the latest closing price.
Terrillion Scott, the SEC’Y; CHIEF COMPLIANCE & G.C. of Cara Therapeutics Inc, sale 2,753 shares at $0.83 during a trade that took place back on Apr 05 ’24, which means that Terrillion Scott is holding 88,247 shares at $2,285 based on the most recent closing price.
Stock Fundamentals for CARA
Current profitability levels for the company are sitting at:
- -5.75 for the present operating margin
- 0.7 for the gross margin
The net margin for Cara Therapeutics Inc stands at -5.61. The total capital return value is set at -1.2. Equity return is now at value -109.80, with -76.94 for asset returns.
Based on Cara Therapeutics Inc (CARA), the company’s capital structure generated 0.39 points at debt to capital in total, while cash flow to debt ratio is standing at -2.48. The debt to equity ratio resting at 0.65. The interest coverage ratio of the stock is 316.61.
Currently, EBITDA for the company is -121.24 million with net debt to EBITDA at 0.07. When we switch over and look at the enterprise to sales, we see a ratio of 1.48. The receivables turnover for the company is 5.22for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.54.
Conclusion
To sum up, Cara Therapeutics Inc (CARA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
